Balaji Amines Receives Warning Letter from FDA

Balaji Amines Ltd has disclosed receipt of a Directions and Warning Letter dated January 10, 2025, from the Food & Drug Administration, Pune. The action stems from a customer's unauthorized resale of technical-grade Propylene Glycol for pharmaceutical use, contravening the Drugs and Cosmetics Act, 1940. The company states there is no material impact on its financials or operations. Balaji Amines has reviewed its sales practices, including clearer invoicing and end-use declarations, to prevent recurrence. The disclosure was made following a SEBI letter dated September 29, 2026, as the company initially believed the letter did not require immediate disclosure.